The global leukapheresis market reached USD 41.78 billion in 2026 and is expected to expand to USD 64.01 billion by 2031, advancing at an 8.9 percent compound annual growth rate. Rising leukemia incidence across aging populations in North America, Europe, and Asia Pacific constitutes the foremost expansion catalyst, driving both therapeutic demand and research applications. The procedure has transitioned from serving primarily as an acute clinical intervention into an indispensable manufacturing component for cell and gene therapy production, particularly supporting CAR-T, TCR, and NK-cell immunotherapy programs that require large-scale white blood cell collection and processing.
What is driving growth
Leukemia prevalence among aging cohorts in developed and developing regions sustains steady baseline demand for leukapheresis as an acute therapeutic intervention to manage elevated white blood cell counts. Beyond this clinical foundation, the explosive growth of cell and gene therapy manufacturing has established leukapheresis as an essential supply-chain function for CAR-T, TCR, and NK-cell therapies, multiplying the end-use applications per patient population. Simultaneously, product enhancements such as Fresenius Kabi’s Amicus Blue ECP upgrades and expanded disposable kit options improve procedural accessibility and user adoption in hospital and blood center settings, sustaining volume increases across markets.
Restraints and challenges
Leukapheresis procedures demand significant capital investment in apheresis equipment, GMP-compliant processing infrastructure, trained personnel, and single-use disposable kits, creating substantial total cost barriers that disproportionately constrain adoption in low- and middle-income regions. Supply-chain disruptions affecting disposable component availability and input cost inflation further compress margins for service providers. Regulatory complexity surrounding blood safety certification, infection control compliance, and cross-border leukopak shipment remains a persistent operational friction point, particularly in emerging markets with less mature quality assurance frameworks.
Segmentation patterns reveal that disposables command a dominant 79.8 percent market share in 2025, reflecting regulatory mandates for infection control and blood safety that favor single-use kits over reusable equipment. Blood component providers and blood centers capture the largest end-user segment at 46 percent, leveraging their established infrastructure and trained personnel to conduct large-scale standardized procedures. Research applications, meanwhile, are forecast to expand at the highest 9.0 percent compound annual rate, driven by accelerating clinical trials in immuno-oncology and cell therapy development across academic and commercial research institutions.
Geographic demand shows pronounced regional variation, with Asia Pacific anticipated to grow fastest at 10.0 percent annually, while North America maintains the largest installed base due to its mature cell therapy manufacturing ecosystem and robust reimbursement landscape. Europe and LAMEA regions support growth through hospital infrastructure upgrades and increased manufacturing capacity investments. Key competitors including Terumo BCT, Fresenius Kabi, Haemonetics Corporation, Grifols S.A., Macopharma, and Medica S.p.A.
Companies profiled
- Terumo BCT
- Fresenius Kabi
- SCTbio
- Rising incidence and prevalence of leukemia
- Haemonetics Corporation
- Grifols S.A
- Macopharma
- Medica S.p.A
For complete market sizing, forecasts, and competitive intelligence, read the full Leukapheresis Market — covering growth drivers, regional analysis, and leading company profiles through 2033.